AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/123
THE USE OF A CATIONIC LIPOSOME FORMULATION (DOTAP) MIXED WITH A RECOMBINANT TUMOR-ASSOCIATED ANTIGEN TO INDUCE IMMUNE-RESPONSES AND PROTECTIVE IMMUNITY IN MICE
Authors: BEI R GUPTILL V MASUELLI L KASHMIRI SVS MURARO R FRATI L SCHLOM J KANTOR J
Citation: R. Bei et al., THE USE OF A CATIONIC LIPOSOME FORMULATION (DOTAP) MIXED WITH A RECOMBINANT TUMOR-ASSOCIATED ANTIGEN TO INDUCE IMMUNE-RESPONSES AND PROTECTIVE IMMUNITY IN MICE, Journal of immunotherapy, 21(3), 1998, pp. 159-169
ENHANCED INTRAPERITONEAL RADIOIMMUNOTHERAPY SALVAGE OF OVARIAN-CANCERWITH ADJUVANT INTERFERON AND TAXOL
Authors: MEREDITH R ALVAREZ R PARTRIDGE E KHAZAELI MB GRIZZLE W MAYO M SCHLOM J LOBUGLIO A
Citation: R. Meredith et al., ENHANCED INTRAPERITONEAL RADIOIMMUNOTHERAPY SALVAGE OF OVARIAN-CANCERWITH ADJUVANT INTERFERON AND TAXOL, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 9-9
EVALUATION OF CH2 DELETED HUCC49 FOR INTRAPERITONEAL RADIOIMMUNOTHERAPY
Authors: BUCHSBAUM DJ KHAZAELI MB MAYO MS HAND PH SCHLOM J MEREDITH RF
Citation: Dj. Buchsbaum et al., EVALUATION OF CH2 DELETED HUCC49 FOR INTRAPERITONEAL RADIOIMMUNOTHERAPY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(1), 1998, pp. 25-25
CHARACTERIZATION OF A NOVEL BISPECIFIC ANTIBODY THAT MEDIATES FC-GAMMA RECEPTOR-TYPE I-DEPENDENT KILLING OF TUMOR-ASSOCIATED GLYCOPROTEIN-72-EXPRESSING TUMOR-CELLS
Authors: RUSSONIELLO C SOMASUNDARAM C SCHLOM J DEO YM KELER T
Citation: C. Russoniello et al., CHARACTERIZATION OF A NOVEL BISPECIFIC ANTIBODY THAT MEDIATES FC-GAMMA RECEPTOR-TYPE I-DEPENDENT KILLING OF TUMOR-ASSOCIATED GLYCOPROTEIN-72-EXPRESSING TUMOR-CELLS, Clinical cancer research, 4(9), 1998, pp. 2237-2243
INTERFERON-GAMMA AND MONOCLONAL-ANTIBODY I-131-LABELED CC49 - OUTCOMES IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER
Authors: SLOVIN SF SCHER HI DIVGI CR REUTER V SGOUROS G MOORE M WEINGARD K PETTENGALL R IMBRIACO M ELSHIRBINY A FINN R BRONSTEIN J BRETT C MILENIC D DNISTRIAN A SHAPIRO L SCHLOM J LARSON SM
Citation: Sf. Slovin et al., INTERFERON-GAMMA AND MONOCLONAL-ANTIBODY I-131-LABELED CC49 - OUTCOMES IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER, Clinical cancer research, 4(3), 1998, pp. 643-651
INTERFERON-GAMMA AND MONOCLONAL-ANTIBODY I-131-LABELED CC49 - OUTCOMES IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER
Authors: SLOVIN SF SCHER HI DIVGI CR REUTER V SGOUROS G MOORE M WEINGARD K PETTENGALL R IMBRIACO M ELSHIRBINY A FINN R BRONSTEIN J BRETT C MILENIC D DNISTRIAN A SHAPIRO L SCHLOM J LARSON SM
Citation: Sf. Slovin et al., INTERFERON-GAMMA AND MONOCLONAL-ANTIBODY I-131-LABELED CC49 - OUTCOMES IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER, Clinical cancer research, 4(3), 1998, pp. 643-651
CONSTRUCTION OF PHOSPHORYLATABLE CHIMERIC MONOCLONAL-ANTIBODY CC49 WITH A TYROSINE SRC KINASE RECOGNITION SITE
Authors: LIN L GILLIES SD SCHLOM J PESTKA S
Citation: L. Lin et al., CONSTRUCTION OF PHOSPHORYLATABLE CHIMERIC MONOCLONAL-ANTIBODY CC49 WITH A TYROSINE SRC KINASE RECOGNITION SITE, International journal of oncology, 13(4), 1998, pp. 725-732
CONSTRUCTION OF PHOSPHORYLATABLE CHIMERIC MONOCLONAL-ANTIBODY CC49
Authors: LIN L GILLIES SD LAN Y IZOTOVA L WU W SCHLOM J PESTKA S
Citation: L. Lin et al., CONSTRUCTION OF PHOSPHORYLATABLE CHIMERIC MONOCLONAL-ANTIBODY CC49, International journal of oncology, 13(1), 1998, pp. 115-120
FORMULATION DEVELOPMENT OF POINT-MUTATED P21 RAS-DERIVED SYNTHETIC PEPTIDES
Authors: GUPTA SL GUPTA S ANDERSON B SCHLOM J
Citation: Sl. Gupta et al., FORMULATION DEVELOPMENT OF POINT-MUTATED P21 RAS-DERIVED SYNTHETIC PEPTIDES, Annals of oncology, 9, 1998, pp. 179-179
VACCINATION OF CANCER-PATIENTS CARRYING RAS MUTATIONS
Authors: KHLEIF SN ABRAMS S BASTIAN A BERGMANN E CHEN A CHUNG Y HAMILTON JM KOHLER DR MORRISON G SCHLOM J ALLEGRA C
Citation: Sn. Khleif et al., VACCINATION OF CANCER-PATIENTS CARRYING RAS MUTATIONS, Annals of oncology, 9, 1998, pp. 325-325
GENERATION OF CEA PEPTIDE-SPECIFIC CYTOTOXIC T-CELLS IN-VIVO FROM HLA-A2.1K(B) TRANSGENIC MICE USING PEPTIDE-PULSED BONE-MARROW (BM)-DERIVED DENDRITIC CELLS (DC)
Authors: TSANG KY CORREALE P ZHU M TERASAWA H ARLEN P ZAREMBA S SCHLOM J
Citation: Ky. Tsang et al., GENERATION OF CEA PEPTIDE-SPECIFIC CYTOTOXIC T-CELLS IN-VIVO FROM HLA-A2.1K(B) TRANSGENIC MICE USING PEPTIDE-PULSED BONE-MARROW (BM)-DERIVED DENDRITIC CELLS (DC), The FASEB journal, 12(4), 1998, pp. 1613-1613
GENERATION OF MURINE WILD-TYPE P53 PEPTIDE-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES THAT LYSE TUMOR-CELLS, BUT NOT NORMAL-CELLS - IMPLICATIONSFOR THE DEVELOPMENT OF P53-BASED CANCER IMMUNOTHERAPIES
Authors: HILBURGER ME SCHLOM J ABRAMS SI
Citation: Me. Hilburger et al., GENERATION OF MURINE WILD-TYPE P53 PEPTIDE-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES THAT LYSE TUMOR-CELLS, BUT NOT NORMAL-CELLS - IMPLICATIONSFOR THE DEVELOPMENT OF P53-BASED CANCER IMMUNOTHERAPIES, The FASEB journal, 12(4), 1998, pp. 1683-1683
IN-VIVO EVALUATION OF A LEAD-LABELED MONOCLONAL-ANTIBODY USING THE DOTA LIGAND
Authors: MILENIC DE ROSELLI M BRECHBIEL MW PIPPIN CG MCMURRAY TJ CARRASQUILLO JA COLCHER D LAMBRECHT R GANSOW OA SCHLOM J
Citation: De. Milenic et al., IN-VIVO EVALUATION OF A LEAD-LABELED MONOCLONAL-ANTIBODY USING THE DOTA LIGAND, European journal of nuclear medicine, 25(5), 1998, pp. 471-480
GENERATION OF HUMAN CYTOLYTIC T-LYMPHOCYTE LINES DIRECTED AGAINST PROSTATE-SPECIFIC ANTIGEN (PSA) EMPLOYING A PSA OLIGOEPITOPE PEPTIDE
Authors: CORREALE P WALMSLEY K ZAREMBA S ZHU MZ SCHLOM J TSANG KY
Citation: P. Correale et al., GENERATION OF HUMAN CYTOLYTIC T-LYMPHOCYTE LINES DIRECTED AGAINST PROSTATE-SPECIFIC ANTIGEN (PSA) EMPLOYING A PSA OLIGOEPITOPE PEPTIDE, The Journal of immunology (1950), 161(6), 1998, pp. 3186-3194
DEVELOPMENT OF A MURINE MUTANT RAS CD8(-I BINDING AND IMMUNOGENIC PROPERTIES() CTL PEPTIDE EPITOPE VARIANT THAT POSSESSES ENHANCED MHC CLASS)
Authors: BRISTOL JA SCHLOM J ABRAMS SI
Citation: Ja. Bristol et al., DEVELOPMENT OF A MURINE MUTANT RAS CD8(-I BINDING AND IMMUNOGENIC PROPERTIES() CTL PEPTIDE EPITOPE VARIANT THAT POSSESSES ENHANCED MHC CLASS), The Journal of immunology, 160(5), 1998, pp. 2433-2441
IDENTIFICATION OF A HUMAN CD8(-LYMPHOCYTE NEO-EPITOPE CREATED BY A RAS CODON-12 MUTATION WHICH IS RESTRICTED BY THE HLA-A2 ALLELE() T)
Authors: BERGMANNLEITNER ES KANTOR JA SHUPERT WL SCHLOM J ABRAMS SI
Citation: Es. Bergmannleitner et al., IDENTIFICATION OF A HUMAN CD8(-LYMPHOCYTE NEO-EPITOPE CREATED BY A RAS CODON-12 MUTATION WHICH IS RESTRICTED BY THE HLA-A2 ALLELE() T), Cellular immunology (Print), 187(2), 1998, pp. 103-116
IN-VITRO GENERATION OF HUMAN CYTOTOXIC T-LYMPHOCYTES SPECIFIC FOR PEPTIDES DERIVED FROM PROSTATE-SPECIFIC ANTIGEN
Authors: CORREALE P WALMSLEY K NIERODA C ZAREMBA S ZHU MZ SCHLOM J TSANG KY
Citation: P. Correale et al., IN-VITRO GENERATION OF HUMAN CYTOTOXIC T-LYMPHOCYTES SPECIFIC FOR PEPTIDES DERIVED FROM PROSTATE-SPECIFIC ANTIGEN, Journal of the National Cancer Institute, 89(4), 1997, pp. 293-300
IMMUNIZATION WITH A SYNGENEIC TUMOR INFECTED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) INDUCES TUMOR-REGRESSION AND LONG-LASTING SYSTEMIC IMMUNITY
Authors: MCLAUGHLIN JP ABRAMS S KANTOR J DOBRZANSKI MJ GREENBAUM J SCHLOM J GREINER JW
Citation: Jp. Mclaughlin et al., IMMUNIZATION WITH A SYNGENEIC TUMOR INFECTED WITH RECOMBINANT VACCINIA VIRUS EXPRESSING GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) INDUCES TUMOR-REGRESSION AND LONG-LASTING SYSTEMIC IMMUNITY, Journal of immunotherapy, 20(6), 1997, pp. 449-459
A CDR-GRAFTED (HUMANIZED) DOMAIN-DELETED ANTITUMOR ANTIBODY
Authors: SLAVINCHIORINI DC KASHMIRI SVS LEE HS MILENIC DE POOLE DJ BERNON E SCHLOM J HAND PH
Citation: Dc. Slavinchiorini et al., A CDR-GRAFTED (HUMANIZED) DOMAIN-DELETED ANTITUMOR ANTIBODY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(5), 1997, pp. 305-316
CORRELATION OF TOXICITY WITH TREATMENT PARAMETERS FOR I-131 CC49 RADIOIMMUNOTHERAPY IN 3 PHASE-II CLINICAL-TRIALS
Authors: LIU TP MEREDITH RF SALEH MN WHEELER RH KHAZAELI MB PLOTT WE SCHLOM J LOBUGLIO AF
Citation: Tp. Liu et al., CORRELATION OF TOXICITY WITH TREATMENT PARAMETERS FOR I-131 CC49 RADIOIMMUNOTHERAPY IN 3 PHASE-II CLINICAL-TRIALS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(2), 1997, pp. 79-87
EFFECT OF RECOMBINANT ALPHA-INTERFERON ON PHARMACOKINETICS, BIODISTRIBUTION, TOXICITY, AND EFFICACY OF I-131-LABELED MONOCLONAL-ANTIBODY CC49 IN BREAST-CANCER - A PHASE-II TRIAL
Authors: MACEY DJ GRANT EJ KASI L ROSENBLUM MG ZHANG HZ KATZ RL RIEGER PT LEBHERZ D SOUTH M GREINER JW SCHLOM J PODOLOFF DA MURRAY JL
Citation: Dj. Macey et al., EFFECT OF RECOMBINANT ALPHA-INTERFERON ON PHARMACOKINETICS, BIODISTRIBUTION, TOXICITY, AND EFFICACY OF I-131-LABELED MONOCLONAL-ANTIBODY CC49 IN BREAST-CANCER - A PHASE-II TRIAL, Clinical cancer research, 3(9), 1997, pp. 1547-1555
PHENOTYPIC STABILITY OF A CYTOTOXIC T-CELL LINE DIRECTED AGAINST AN IMMUNODOMINANT EPITOPE OF HUMAN CARCINOEMBRYONIC ANTIGEN
Authors: TSANG KY ZHU MZ NIERODA CA CORREALE P ZAREMBA S HAMILTON JM COLE D LAM C SCHLOM J
Citation: Ky. Tsang et al., PHENOTYPIC STABILITY OF A CYTOTOXIC T-CELL LINE DIRECTED AGAINST AN IMMUNODOMINANT EPITOPE OF HUMAN CARCINOEMBRYONIC ANTIGEN, Clinical cancer research, 3(12), 1997, pp. 2439-2449
THERAPEUTIC ANTITUMOR RESPONSE AFTER IMMUNIZATION WITH AN ADMIXTURE OF RECOMBINANT VACCINIA VIRUSES EXPRESSING A MODIFIED MUC1 GENE AND THEMURINE T-CELL COSTIMULATORY MOLECULE B7
Authors: AKAGI J HODGE JW MCLAUGHLIN JP GRITZ L MAZZARA G KUFE D SCHLOM J KANTOR JA
Citation: J. Akagi et al., THERAPEUTIC ANTITUMOR RESPONSE AFTER IMMUNIZATION WITH AN ADMIXTURE OF RECOMBINANT VACCINIA VIRUSES EXPRESSING A MODIFIED MUC1 GENE AND THEMURINE T-CELL COSTIMULATORY MOLECULE B7, Journal of immunotherapy with emphasis on tumor immunology, 20(1), 1997, pp. 38-47
ADOPTIVE IMMUNOTHERAPY AS AN IN-VIVO MODEL TO EXPLORE ANTITUMOR MECHANISMS INDUCED BY A RECOMBINANT ANTICANCER VACCINE
Authors: ABRAMS SI HODGE JW MCLAUGHLIN JP STEINBERG SM KANTOR JA SCHLOM J
Citation: Si. Abrams et al., ADOPTIVE IMMUNOTHERAPY AS AN IN-VIVO MODEL TO EXPLORE ANTITUMOR MECHANISMS INDUCED BY A RECOMBINANT ANTICANCER VACCINE, Journal of immunotherapy with emphasis on tumor immunology, 20(1), 1997, pp. 48-59
CONSTRUCTION AND CHARACTERIZATION OF A RECOMBINANT VACCINIA VIRUS EXPRESSING MURINE INTERCELLULAR-ADHESION MOLECULE-1 - INDUCTION AND POTENTIATION OF ANTITUMOR RESPONSES
Authors: UZENDOSKI K KANTOR JA ABRAMS SI SCHLOM J HODGE JW
Citation: K. Uzendoski et al., CONSTRUCTION AND CHARACTERIZATION OF A RECOMBINANT VACCINIA VIRUS EXPRESSING MURINE INTERCELLULAR-ADHESION MOLECULE-1 - INDUCTION AND POTENTIATION OF ANTITUMOR RESPONSES, Human gene therapy, 8(7), 1997, pp. 851-860
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>